Conference Coverage
Latest News
Shorter courses of chemo treatment taking hold in colon cancer
The IDEA trial has led to a major change in stage III colon cancer treatment. Adjuvant colon cancer therapy is shifting toward the combination...
Latest News
Cost not a factor in radiotherapy type for breast cancer patients
“Hypofractionated radiotherapy represents significant savings to both the health care system and to individual patients. It may soon become the...
Latest News
ctDNA identifies CRC patients who benefit from adjuvant therapy
The study shows that stratifying postsurgical treatment decisions using the assay can identify patients likely to benefit from adjuvant...
Latest News
Dual immunotherapy promising new option for liver cancer
The novel regimen, dubbed STRIDE, comprised a single priming dose of the investigational agent tremelimumab followed by regular doses of...
Latest News
Adding TACE to lenvatinib improves survival in liver cancer
The combination of TACE and lenvatinib "represents a potential new first-line treatment option for patients with advanced HCC."
Latest News
Aspirin use risk for postpartum bleeding unclear
Demographic and clinical factors likely accounted for more of the bleeding risk observed than the low-dose aspirin did, but time of...
Latest News
Confirmed: Pembro plus chemo as first-line standard of care for esophageal cancer
An interim analysis of KEYNOTE-590 found that the combination of pembrolizumab and chemotherapy as first-line treatment, proved superior to...
Latest News
Novel treatment shows early promise for gastric cancer
The AK104 antibody treatment combined with chemotherapy demonstrated a manageable safety profile.
Latest News
Endoscopic mucosal resection valuable for cancer diagnosis
Endoscopic mucosal resection offers advantages over endoscopic submucosal dissection for most Barrett’s esophagus.
Latest News
Decades of research fail to resolve disparities in gastrointestinal cancer care
Women, Blacks, and Latinos still dying from gastroesophageal cancer at higher rates than men and Whites in general.
Latest News
Can immunotherapy replace surgery for stomach cancer?
The complete pathologic response rate to neoadjuvant nivolumab/ipilimumab was 59%.